ArticlePharmaceutical research2026
Pharmaceutical Stability of Romiplostim: In-use Functional Study Using Microscale Thermophoresis New Strategy and Elisa.
Article in Pharmaceutical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveFunctional stability is crucial for therapeutic proteins at all stages of their lifecycle. Romiplostim (Nplate®) is world-wide used for treating immune thrombocytopenia purpura. Limited in-use stability data on the proper romiplostim handling is publicly available. This study aimed to evaluate romiplostin in-use functional stability focusing on the interaction with its therapeutic target (TPO-R) and to improve the existing functional assessment strategies by developing a new one using microscale thermophoresis (MST).
methodsReconstituted romiplostim (Nplate®) samples were analysed. MST and ELISA functional methods were developed and optimized ad hoc to assess romiplostim functional stability. Far-UV-Circular-Dichroism and Intrinsic-Tryptophan-Fluorescence-Spectroscopy were used to ensure MST results by confirming the conformational stability of labelled TPO-R. In-use stability was assessed by subjecting romiplostim to conditions related to hospital handling, e.g. agitation and exposure to natural light; also, freezing and artificial light irradiation were checked as forced degraded condition.
resultsMST and ELISA were described and validated by their figures of merit. Regarding romiplostim functional stability, both approaches yielded similar stability profiles, but MST detected subtle functional declines that were not revealed by ELISA. Furthermore, MST revealed insights into romiplostim binding stoichiometry, suggesting 1:2 interaction at high concentrations.
conclusionRegarding functionality, romiplostim was particularly sensitive to light exposure, with less sensitivity to agitation and freezing. These findings also demonstrate that MST serves as new orthogonal strategy to ELISA for assessing functionality, even providing additional data on binding dynamics and stoichiometry. This new MST strategy is applicable for any type of functional study of therapeutic proteins.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.